Exclusive Online Content
Teneobio's Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine Release
Teneobio, Inc, a next-generation antibody therapeutics company, recently announced the discovery of a large panel of human anti-CD3 binders with diverse affinities and tune-able T-cell…
Genisphere Begins Collaborative & Sponsored Research Program With the University of Maryland
Genisphere LLC, provider of the 3DNA® drug delivery platform, has signed a collaborative and sponsored research agreement with the University of Maryland, through Dr. Silvia…
Pharmatek Adds Further cGMP Spray Drying Capacity in Response to Demand for Improved Pharmaceutical Solubility
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently announced that it…
Genisphere Begins Collaborative & Sponsored Research Program With the University of Maryland
Genisphere LLC, provider of the 3DNA® drug delivery platform, has signed a collaborative and sponsored research agreement with the University of Maryland, through Dr. Silvia…
Pharmatek Adds Further cGMP Spray Drying Capacity in Response to Demand for Improved Pharmaceutical Solubility
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, recently announced that it…
Q BioMed Announces Licensing Agreement
Q BioMed Inc. (QBIO) and ASDERA LLC recently announced a licensing agreement that provides Q BioMed with the worldwide exclusive rights to ASDERA's ASD-002, which is…
Q BioMed Announces Licensing Agreement
Q BioMed Inc. (QBIO) and ASDERA LLC recently announced a licensing agreement that provides Q BioMed with the worldwide exclusive rights to ASDERA's ASD-002, which is…
SteadyMed Raises $30 Million
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery…
SteadyMed Raises $30 Million
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery…
Crown Bioscience Launches e-Commerce Platform to Commercialize its Life Science Products
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to…
Crown Bioscience Launches e-Commerce Platform to Commercialize its Life Science Products
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to…
Pipeline Drug Offers Promise in Treatment of Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine, a drug currently being trialed by ImmunoGen, has the potential to solve a major unmet medical need for patients with platinum-resistant ovarian cancer,…
Pipeline Drug Offers Promise in Treatment of Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine, a drug currently being trialed by ImmunoGen, has the potential to solve a major unmet medical need for patients with platinum-resistant ovarian cancer,…
Aptar Pharma Unveils its eDose Counter for MDIs at RDD Europe 2017
Aptar Pharma recently announced it will present its patented eDose Counter for Metered Dose Inhalers (MDIs), designed to be easy-to-use and reliable, and contributes to…
Aptar Pharma Unveils its eDose Counter for MDIs at RDD Europe 2017
Aptar Pharma recently announced it will present its patented eDose Counter for Metered Dose Inhalers (MDIs), designed to be easy-to-use and reliable, and contributes to…
MedCision Announces the ThawSTAR Early Adopter Program for Limited Time
MedCision, a leader in the automation of basic clinical processes, recently announced the ThawSTAR Cell Thawing Early Adopter Program for companies undergoing early cell therapy…
MedCision Announces the ThawSTAR Early Adopter Program for Limited Time
MedCision, a leader in the automation of basic clinical processes, recently announced the ThawSTAR Cell Thawing Early Adopter Program for companies undergoing early cell therapy…
HealthFactors Announces Collaboration With Koronis Biomedical Technologies
HealthFactors, Inc. and Koronis Biomedical Technologies (KBT) recently announced a formal collaboration designed to improve healthcare and outcomes for people with respiratory conditions associated with…
HealthFactors Announces Collaboration With Koronis Biomedical Technologies
HealthFactors, Inc. and Koronis Biomedical Technologies (KBT) recently announced a formal collaboration designed to improve healthcare and outcomes for people with respiratory conditions associated with…
Aptar Pharma's Preservative-Free Multidose Dispenser Chosen for the First Time
Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser is available for patients in the US prescription market for the first time with Allergan’s…
